Phreesia医疗支付
PHR
10.94
-0.10
-0.91%
Phreesia医疗支付
US · PHR
#3570 按市值排名
上市于 2019
10.94
-0.10
-0.91%
实时 - 追踪5344个代码 - 心跳于514秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 98.68% -0.30pp
- 机构数量
- 277
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund59.80%
Hedge Fund15.42%
VC/PE Fund14.38%
Individual/Insider6.29%
Private Company3.94%
Public Company3.13%
Insurance Company1.12%
Government Pension Fund0.68%
Family Office/Trust0.15%
主要股东 截至 2026-06-30
Pale Fire Capital SE
14.38% · 8.92M 股
BlackRock
11.31% · 7.02M 股
AQR Capital Management
4.95% · 3.07M 股
Vanguard Portfolio Management, LLC
4.81% · 2.99M 股
Vanguard Capital Management, LLC
4.76% · 2.95M 股
Acadian Asset Management LLC
2.59% · 1.60M 股
State Street Global Advisors
2.54% · 1.58M 股
T. Rowe Price Group, Inc.
2.26% · 1.41M 股
Chaim Indig
2.21% · 1.37M 股
Geode Capital Management, LLC
2.11% · 1.31M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 31次买入 · 19次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Pale Fire Capital SE | -- | 14.38% |
| Chaim Indig | Chief Executive Officer | 2.21% |
| Evan Roberts | Co-Founder & COO | 1.67% |
| David Linetsky | Senior Vice President of Life Sciences | 0.71% |
| Balaji Gandhi | Chief Financial Officer | 0.56% |
| Amy VanDuyn | Officer | 0.42% |
| Michael Weintraub | Independent Chairperson | 0.30% |
| Edward Cahill | Independent Director | 0.11% |
| Yvonne Hui | VP & Principal Accounting Officer | 0.10% |
| Allison Hoffman | General Counsel | 0.08% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-20 | Allison Hoffman | General Counsel | Automatic Disposition | -6,662 | $10.08 |
| 2026-09-17 | Allison Hoffman | General Counsel | Sale to Issuer | -7,401 | $10.42 |
| 2026-09-17 | Evan Roberts | Co-Founder & COO | Sale to Issuer | -4,476 | $10.42 |
| 2026-09-17 | Amy VanDuyn | Officer | Sale to Issuer | -2,876 | $10.42 |
| 2026-09-17 | David Linetsky | Senior Vice President of Life Sciences | Sale to Issuer | -4,794 | $10.42 |
| 2026-09-13 | Allison Hoffman | General Counsel | Other Acquisition | +14,063 | -- |
| 2026-09-13 | Evan Roberts | Co-Founder & COO | Other Acquisition | +8,113 | -- |
| 2026-09-13 | Amy VanDuyn | Officer | Other Acquisition | +6,490 | -- |
| 2026-09-13 | David Linetsky | Senior Vice President of Life Sciences | Other Acquisition | +8,816 | -- |
| 2026-08-31 | Allison Hoffman | General Counsel | Other Acquisition | +108,000 | -- |
| 2026-08-31 | Allison Hoffman | General Counsel | Other Derivative Acquisition | +85,000 | -- |
| 2026-08-31 | Balaji Gandhi | Chief Financial Officer | Other Acquisition | +192,000 | -- |
| 2026-08-31 | Balaji Gandhi | Chief Financial Officer | Other Derivative Acquisition | +155,000 | -- |
| 2026-08-31 | Chaim Indig | Chief Executive Officer | Other Acquisition | +500,000 | -- |
| 2026-08-31 | Chaim Indig | Chief Executive Officer | Other Derivative Acquisition | +400,000 | -- |
| 2026-08-31 | Evan Roberts | Co-Founder & COO | Other Acquisition | +192,000 | -- |
| 2026-08-31 | Evan Roberts | Co-Founder & COO | Other Derivative Acquisition | +155,000 | -- |
| 2026-08-31 | Amy VanDuyn | Officer | Other Acquisition | +88,000 | -- |
| 2026-08-31 | Amy VanDuyn | Officer | Other Derivative Acquisition | +67,500 | -- |
| 2026-08-31 | David Linetsky | Senior Vice President of Life Sciences | Other Acquisition | +202,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Phreesia医疗支付 讨论区 0 条评论